Castration Resistant Prostate Cancer Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Castration Resistant Prostate Cancer stocks.

Castration Resistant Prostate Cancer Stocks Recent News

Date Stock Title
May 21 AMGN Amgen, Inc. (AMGN) ATS and the Approval of IMDELLTRA Conference - (Transcript)
May 20 AMGN Amgen/AstraZeneca Say Asthma Drug Shows Activity In Another Lung Disease Across Broad Patient Population
May 20 AMGN AstraZeneca, Amgen release mid-stage data on Tezspire for COPD
May 20 AMGN The Zacks Analyst Blog Highlights Stocks recently featured in the blog include: Novo Nordisk, Eli Lilly's, Viking, Altimmune, Roche and Amgen
May 19 AMGN NEW DATA PRESENTED AT ATS 2024 SHOW THE POTENTIAL OF TEZSPIRE® TO HELP PATIENTS LIVING WITH COPD
May 19 AMGN Is Amgen a Threat to Eli Lilly in This Billion-Dollar Market?
May 18 AMGN Cannabis Meets Prescription Drugs, Steroids And Ketamine In Schedule III: What It Means, Key Stocks To Watch
May 17 AMGN 4 Stocks That Could Break Novo Nordisk, Lilly's Obesity Duopoly
May 17 AMGN Amgen's (AMGN) Tarlatamab Receives FDA Approval for SCLC
May 17 AMGN Meet the GLP-1 Drug That Could Be the Biggest Concern for Eli Lilly and Novo Nordisk
May 17 AMGN FDA approves Amgen drug for tough-to-treat form of lung cancer
May 17 AMGN Amgen’s IMDELLTRA receives FDA approval for lung cancer treatment
May 16 AMGN FDA APPROVES IMDELLTRA™ (TARLATAMAB-DLLE), THE FIRST AND ONLY T-CELL ENGAGER THERAPY FOR THE TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG CANCER
May 16 AMGN Amgen wins FDA nod for new lung cancer therapy
May 16 AMGN KRAS inhibitors: The next frontier beckons
May 15 AMGN AMGEN TO HOST CONFERENCE CALL FOLLOWING ATS 2024
May 15 AMGN Amgen Inc's Dividend Analysis
May 14 AMGN Amgen Inc. (AMGN) BofA Securities 2024 Health Care Conference (Transcript)
Castration Resistant Prostate Cancer

Castration-resistant prostate cancer (CRPC) is a type of prostate cancer that is resistant to hormone therapy, which is the primary treatment for prostate cancer. It is also known as hormone-refractory prostate cancer (HRPC). CRPC is an advanced form of prostate cancer that has spread beyond the prostate gland and is no longer responding to hormone therapy. It is usually treated with chemotherapy, radiation therapy, and other treatments.

Browse All Tags